Acadia Healthcare - ACHC Stock Forecast, Price & News

Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or 24-hour observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and offer therapeutic placement for children and adolescents with emotional disorders. As of February 28, 2022, it operated a network of 228 behavioral healthcare facilities with approximately 10,500 beds. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ACHC shares. UBS Group lifted their price objective on Acadia Healthcare from $82.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, July 28th. Loop Capital started coverage on shares of Acadia Healthcare in a research report on Thursday, June 16th. They set a "hold" rating and a $72.00 price objective on the stock. BMO Capital Markets lifted their target price on shares of Acadia Healthcare from $67.00 to $82.00 in a research note on Friday, May 6th. Mizuho increased their price target on shares of Acadia Healthcare from $64.00 to $69.00 in a research note on Wednesday, May 4th. Finally, Jefferies Financial Group lifted their price objective on Acadia Healthcare from $85.00 to $95.00 in a research report on Thursday, July 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Acadia Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $81.89.

Acadia Healthcare Stock Up 0.0 %

NASDAQ:ACHC traded up $0.02 during mid-day trading on Monday, hitting $82.63. 408,420 shares of the company's stock were exchanged, compared to its average volume of 575,144. The company has a market cap of $7.51 billion, a PE ratio of 27.09, a P/E/G ratio of 2.12 and a beta of 1.30. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.17 and a quick ratio of 1.17. Acadia Healthcare has a one year low of $50.07 and a one year high of $83.63. The business has a fifty day moving average price of $73.79 and a 200 day moving average price of $67.99.

Acadia Healthcare (NASDAQ:ACHC - Get Rating) last released its earnings results on Wednesday, July 27th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.07. The firm had revenue of $651.72 million during the quarter, compared to analyst estimates of $650.80 million. Acadia Healthcare had a net margin of 11.32% and a return on equity of 10.34%. The business's revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $0.71 earnings per share. Equities analysts predict that Acadia Healthcare will post 3.13 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Christopher L. Howard sold 12,214 shares of the firm's stock in a transaction on Monday, August 8th. The stock was sold at an average price of $81.67, for a total transaction of $997,517.38. Following the completion of the transaction, the executive vice president now directly owns 149,147 shares in the company, valued at $12,180,835.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Christopher L. Howard sold 12,214 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $81.67, for a total transaction of $997,517.38. Following the sale, the executive vice president now directly owns 149,147 shares of the company's stock, valued at approximately $12,180,835.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John S. Hollinsworth sold 10,780 shares of Acadia Healthcare stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $80.68, for a total transaction of $869,730.40. Following the completion of the transaction, the executive vice president now directly owns 80,559 shares of the company's stock, valued at $6,499,500.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,094 shares of company stock valued at $2,375,868. 1.90% of the stock is currently owned by corporate insiders.